535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results
Regular and Young Investigator Award Abstracts | November 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: A611-A612
10.1136/jitc-2025-sitc2025.0535